[go: up one dir, main page]

WO2000066156A8 - Death domain containing receptor 5 - Google Patents

Death domain containing receptor 5

Info

Publication number
WO2000066156A8
WO2000066156A8 PCT/US2000/012041 US0012041W WO0066156A8 WO 2000066156 A8 WO2000066156 A8 WO 2000066156A8 US 0012041 W US0012041 W US 0012041W WO 0066156 A8 WO0066156 A8 WO 0066156A8
Authority
WO
WIPO (PCT)
Prior art keywords
domain containing
death domain
containing receptor
proteins
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/012041
Other languages
French (fr)
Other versions
WO2000066156A1 (en
Inventor
Jian Ni
Reiner L Gentz
Guo-Liang Yu
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP00930329A priority Critical patent/EP1196191A4/en
Priority to AU48172/00A priority patent/AU4817200A/en
Priority to JP2000615040A priority patent/JP2002543151A/en
Priority to CA002369371A priority patent/CA2369371A1/en
Publication of WO2000066156A1 publication Critical patent/WO2000066156A1/en
Publication of WO2000066156A8 publication Critical patent/WO2000066156A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR5 acitivity.
PCT/US2000/012041 1999-05-04 2000-05-04 Death domain containing receptor 5 Ceased WO2000066156A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00930329A EP1196191A4 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5
AU48172/00A AU4817200A (en) 1999-05-04 2000-05-04 Death domain containing receptor 5
JP2000615040A JP2002543151A (en) 1999-05-04 2000-05-04 Death domain containing receptor 5
CA002369371A CA2369371A1 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13249899P 1999-05-04 1999-05-04
US13323899P 1999-05-07 1999-05-07
US14893999P 1999-08-13 1999-08-13
US60/133,238 1999-08-13
US60/148,939 1999-08-13
US60/132,498 1999-08-13

Publications (2)

Publication Number Publication Date
WO2000066156A1 WO2000066156A1 (en) 2000-11-09
WO2000066156A8 true WO2000066156A8 (en) 2001-07-26

Family

ID=27384298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012041 Ceased WO2000066156A1 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5

Country Status (5)

Country Link
EP (1) EP1196191A4 (en)
JP (1) JP2002543151A (en)
AU (1) AU4817200A (en)
CA (1) CA2369371A1 (en)
WO (1) WO2000066156A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314619B2 (en) 1997-05-15 2008-01-01 Genentech, Inc. Inducing apoptosis using anti-Apo-2 antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
JP3665316B2 (en) 2001-05-18 2005-06-29 麒麟麦酒株式会社 Anti-TRAIL-R antibody
DK1572874T3 (en) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antibodies that immunospecifically bind to TRAIL receptors
WO2003038087A1 (en) * 2001-10-04 2003-05-08 Kansai Technology Licensing Organization Co., Ltd. DR5 GENE PROMOTER AND Siah-1 GENE PROMOTER
JP2007533595A (en) * 2003-03-26 2007-11-22 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of viral infection
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2005114187A2 (en) * 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
EP1846034A4 (en) 2005-02-02 2010-11-10 Uab Research Foundation AGENTS AND METHODS FOR REDUCING AGONIST RESISTANCE OF APOPTOSIS-INDUCING DEATH RECEPTORS
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
KR20120101050A (en) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
JP6219923B2 (en) * 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Combination of DR5 receptor agonists
ES2644022T3 (en) 2013-03-14 2017-11-27 Bristol-Myers Squibb Company Combination of a DR5 agonist and an anti-PD-1 antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
NZ337795A (en) * 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
DK1181319T3 (en) * 1999-05-28 2009-08-17 Genentech Inc Chimeric DR4 antibodies and uses thereof
PT1192185E (en) * 1999-06-09 2006-11-30 Genentech Inc Apo-2l receptor agonist and cpt-11 synergism
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314619B2 (en) 1997-05-15 2008-01-01 Genentech, Inc. Inducing apoptosis using anti-Apo-2 antibodies
US7595046B2 (en) 1997-05-15 2009-09-29 Genentech, Inc. Treatment of cancer using anti-Apo-2 antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
EP1196191A1 (en) 2002-04-17
EP1196191A4 (en) 2004-03-24
WO2000066156A1 (en) 2000-11-09
CA2369371A1 (en) 2000-11-09
JP2002543151A (en) 2002-12-17
AU4817200A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
CA2285040A1 (en) Death domain containing receptor 5
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
WO2000066156A8 (en) Death domain containing receptor 5
WO1998030693A3 (en) Tumor necrosis factor receptor 5
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP1003767A4 (en) Human tumor necrosis factor receptor tr10
WO2001055308A3 (en) Nucleic acids, proteins, and antibodies
WO2000054651A3 (en) Human tumor necrosis factor receptor-like genes
WO2000067793A8 (en) Death domain containing receptor 4
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
AU5166200A (en) Human tumor necrosis factor receptor tr10
WO2001005834A9 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
WO1999042586A3 (en) Exo1 and exo2, exocytotic proteins
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2002057421A3 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
EP1865061A3 (en) IL-17 homologous polypeptides and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
ENP Entry into the national phase in:

Ref document number: 2369371

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 615040

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2369371

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000930329

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000930329

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000930329

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)